Quantcast

Latest Regenerative medicine Stories

2014-09-10 16:24:07

Media Company Mary Ann Liebert, Inc., Makes Foray from Scientific & Medical Journals to Consumer Arena with Launch of New Non-Fiction Work Inevitable Collision NEW ROCHELLE, New York, Sept. 10, 2014 /PRNewswire/ -- Mary Ann Liebert, Inc., leading publisher of over 80 science, technology, and medical publications, announced today the launch of first time hard cover title Inevitable Collision: The Inspiring Story that Brought Stem Cell Research to Conservative America, in an effort to...

2014-08-29 23:09:59

Now approaching the one-year mark since its founding, The Adult Stem Cell Technology Center, LLC (ASCTC) in Boston, Massachusetts has lined-up participation in three conferences focused on stem cells and regenerative medicine over the next two months. At two of the conferences, ASCTC Director James Sherley will provide updates on the company’s progress with development of its new technology for detecting drug candidates that are toxic to tissue stem cells. Boston, MA (PRWEB) August 29,...

2014-08-27 23:00:26

Upcoming New York Adult Stem Cell Lecture on Wednesday, September 3, 2014, at 2pm and 4pm at the City Limits Diner, at 135 Harvard Avenue, Stamford, CT 06902 New York, California (PRWEB) August 28, 2014 The Manhattan Regenerative Medicine Medical Group announces a series of free public seminars on the use of adult stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief, and, Dr. Nia M. Smyrniotis, Medical Director....

Organ Grown In Living Animal From Cells Created In Lab
2014-08-26 03:32:07

University of Edinburgh Laboratory-grown replacement organs have moved a step closer with the completion of a new study. Scientists have grown a fully functional organ from transplanted laboratory-created cells in a living animal for the first time. The researchers have created a thymus - an organ next to the heart that produces immune cells known as T cells that are vital for guarding against disease. They hope that, with further research, the discovery could lead to new...

2014-08-25 08:26:56

Clinical Grade Cell and Tissue Biopreservation Media Products Enabling Commercialization of Cellular Immunotherapies and Restorative Therapies BOTHELL, Wash., Aug. 25, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today provided an update on adoption of the...

2014-08-22 23:05:15

In a new study published in STEM CELLS Translational Medicine on July 14, 2014, researchers from Tokyo Medical and Dental University along with a team from Osaka University may have found a potentially powerful approach for creating human induced pluripotent stem cells (hiPSCs) for clinical use. Durham, NC (PRWEB) August 22, 2014 Human induced pluripotent stem cells (hiPSCs) have great potential in the field of regenerative medicine because they can be coaxed to turn into specific cells;...

2014-08-22 23:05:03

Cryo-Cell International, Inc., the world’s first cord blood bank, announced today that it has provided funding to complete an Investigational New Drug Application (IND) for a FDA approved Phase I clinical trial for patients that have amyotrophic lateral sclerosis (ALS or Lou Gehrig's) disease using umbilical cord blood cells. Oldsmar, FL (PRWEB) August 22, 2014 This funding was made through an additional investment in Cryo-Cell’s cell therapy research affiliate, Saneron CCEL...

2014-08-21 08:29:07

SAN DIEGO, Aug. 21, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately held regenerative medicine company announced today that it has entered into a Rights Agreement with Janssen Research & Development LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement provides Janssen with a future right to evaluate a transaction related to the VC-01(TM) combination product that ViaCyte is developing for type 1 diabetes. This right will continue...

2014-08-19 08:30:47

Company Plans to Immediately Initiate Phase 1/2 Clinical Trial SAN DIEGO, Aug. 19, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the U.S. Food and Drug Administration ("FDA") has accepted the company's Investigational New Drug Application ("IND") for its VC-01(TM) candidate cell replacement therapy to treat type 1 diabetes. The company plans to promptly initiate a Phase 1/2 clinical trial which it believes to be the first...

2014-08-14 16:26:32

DUBLIN, Aug. 14, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the Global Regenerative Medicine (Stem Cell Therapy, Biomaterial and Tissue Engineering) Market (Bone and Joint) - Forecast to 2019" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 U.S. National Institute of Health stated that regenerative medicine is the process of creating functional tissue to repair and replace tissue or organ which has lost their function due to damage,...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related